EditForce, Inc.
Fukuoka, JP· latest recorded location
EditForce, Inc. is named on 2 US grants and 5 published applications in this corpus. Its most frequent classification is C12N (Microorganisms or enzymes).
- Granted patents
- 2
- Published applications
- 5
- Inventors
- 13
- Granted in 2026 so far
- 2
- Most recent grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2022 | 0 | 2 |
| 2023 | 0 | 2 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
| 2026 | 2 | 0 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 7 documents
Recent patents
- FokI nuclease domain mutant26 May 2026US 12,637,667 B2
- PPR protein causing less aggregation and use of the same24 Feb 2026US 12,559,528 B2
- Therapeutic drug for myotonic dystrophy type 111 Sep 2025US 2025/0281571 A1
- Foki nuclease domain mutant28 Dec 2023US 2023/0416709 A1
- Method for editing target rna27 Apr 2023US 2023/0125942 A1
- Efficient method for preparing ppr protein and use of the same15 Sep 2022US 2022/0289795 A1
- Ppr protein causing less aggregation and use of the same14 Jul 2022US 2022/0220166 A1
Most cited
By later US patents
None of its patents has been cited by a later US patent yet.